14国耐多药结核患者同时使用贝达喹啉、德拉马尼及其他二线药物的安全性和有效性结局
本研究为多中心前瞻性观察队列,覆盖14个国家,纳入2015年4月至2018年9月接受贝达喹啉(Bdq)与德拉马尼(Dlm)联合治疗的耐多药/利福平耐药结核(MDR/RR-TB)患者,随访至治疗结束。472例患者中78.0%(358/458)获得治疗成功,8.9%死亡,7.2%治疗失败;作者认为该联合方案对广泛病变的MDR/RR-TB患者安全有效。
要点
- 472例同时使用Bdq与Dlm,78.0%(358/458)治疗成功,8.9%死亡,7.2%治疗失败。
- 最常见不良事件为周围神经病变28.4%和电解质耗竭19.9%,QT延长1.5%。
- 作者认为Bdq与Dlm联用对广泛病变、多重耐药的MDR/RR-TB是良好治疗选择。
核心结论
- 同时使用Bdq与Dlm并联合利奈唑胺和氯法齐明,对广泛病变的MDR/RR-TB患者安全有效。
- 作者认为同时使用这些药物对耐多种抗结核药物的患者是良好的治疗选择。
研究设计与样本
- 多中心前瞻性观察队列研究,覆盖14个国家,纳入2015年4月至2018年9月接受Bdq与Dlm同时治疗的患者,随访至治疗结束。
- 共472例患者同时接受Bdq和Dlm治疗,其中89.6%同时使用利奈唑胺,84.5%同时使用氯法齐明。
主要发现
- 90.3%的患者有广泛病变,74.2%对氟喹诺酮类耐药。
- 最常见的不良事件为周围神经病变134例(28.4%)和电解质耗竭94例(19.9%)。
- 急性肾损伤40例(8.5%),骨髓抑制24例(5.1%),QT延长7例(1.5%)。
- 78.0%(358/458)获得治疗成功,8.9%死亡,7.2%治疗失败。
临床怎么用
- 作者认为,对耐多种抗结核药物的MDR/RR-TB患者,同时使用Bdq与Dlm是良好的治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-benefit ratio. Yet this combination is an important alternative for patients infected with strains of TB with complex drug resistance profiles or who cannot tolerate other therapies. We assessed safety and treatment outcomes of MDR/RR-TB patients receiving concomitant Bdq and Dlm, along with other second-line anti-TB drugs. METHODS: We conducted a multi-centric, prospective observational cohort study across 14 countries among patients receiving concomitant Bdq-Dlm treatment. Patients were recruited between April 2015 and September 2018 and were followed until the end of treatment. All serious adverse events and adverse events of special interest (AESI), leading to a treatment change, or judged significant by a clinician, were systematically monitored and documented. RESULTS: Overall, 472 patients received Bdq and Dlm concomitantly. A large majority also received linezolid (89.6%) and clofazimine (84.5%). Nearly all (90.3%) had extensive disease; most (74.2%) had resistance to fluoroquinolones. The most common AESI were peripheral neuropathy (134, 28.4%) and electrolyte depletion (94, 19.9%). Acute kidney injury and myelosuppression were seen in 40 (8.5%) and 24 (5.1%) of patients, respectively. QT prolongation occurred in 7 patients (1.5%). Overall, 78.0% (358/458) had successful treatment outcomes, 8.9% died, and 7.2% experienced treatment failure. CONCLUSIONS: Concomitant use of Bdq and Dlm, along with linezolid and clofazimine, is safe and effective for MDR/RR-TB patients with extensive disease. Using these drugs concomitantly is a good therapeutic option for patients with resistance to many anti-TB drugs.
引用
- Huerga H, Khan U, Bastard M, et al. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. Clin Infect Dis. 2022. PMID: 35243494. doi:10.1093/cid/ciac176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。